Organovo Holdings, Inc. Files S-1/A Amendment

TL;DR

<b>Organovo Holdings, Inc. filed an S-1/A amendment on April 30, 2024, detailing its corporate information and regulatory filings.</b>

AI Summary

ORGANOVO HOLDINGS, INC. (VIVS) filed a Amended IPO Registration (S-1/A) with the SEC on April 30, 2024. Organovo Holdings, Inc. (formerly Real Estate Restoration & Rental, Inc.) filed an S-1/A amendment on April 30, 2024. The company is incorporated in Delaware with its fiscal year ending March 31. Its business and mailing address is 11555 Sorrento Valley Road, Suite 100, San Diego, CA 92121. The filing relates to the Securities Act of 1933. The SIC code is 2836 for Biological Products (No Diagnostic Substances).

Why It Matters

For investors and stakeholders tracking ORGANOVO HOLDINGS, INC., this filing contains several important signals. This S-1/A filing provides updated information for investors and regulatory bodies regarding Organovo Holdings' corporate structure and compliance. The amendment signifies ongoing activity and potential future actions by Organovo Holdings, Inc. that require public disclosure.

Risk Assessment

Risk Level: low — ORGANOVO HOLDINGS, INC. shows low risk based on this filing. The filing is an amendment to a registration statement (S-1/A), indicating routine corporate disclosure rather than a significant event or financial distress.

Analyst Insight

Monitor future filings for details on the company's business activities and financial performance.

Key Numbers

• S-1/A — Form Type (Filing type)
• 20240430 — Filing Date (Date of filing)
• 0000950170-24-050663 — Accession Number (Unique identifier for the filing)
• 333-278668 — SEC File Number (SEC's file number for the company)

Key Players & Entities

• ORGANOVO HOLDINGS, INC. (company) — Filer name
• REAL ESTATE RESTORATION & RENTAL, INC. (company) — Former company name
• 20100722 (date) — Date of name change
• 11555 SORRENTO VALLEY ROAD (address) — Business and mailing street address
• SAN DIEGO (location) — Business and mailing city
• DE (location) — State of incorporation
• 0331 (date) — Fiscal year end
• 2836 (industry_code) — Standard Industrial Classification

FAQ

Industry Context

Organovo Holdings, Inc. operates in the Biological Products sector, specifically under SIC code 2836.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1/A filing for detailed business descriptions and financial information.
2. Track future SEC filings from Organovo Holdings, Inc. for updates on operations and strategy.
3. Research the company's market position within the biological products industry.

Key Dates

• 2024-04-30: S-1/A Filing — Amendment to registration statement filed by Organovo Holdings, Inc.
• 2010-07-22: Name Change — Date Organovo Holdings, Inc. changed its name from Real Estate Restoration & Rental, Inc.

Year-Over-Year Comparison

This is an S-1/A filing, indicating an amendment to a previous registration statement. Specific comparative data from a prior filing is not detailed here.

Key Financial Figures

• $1 — tock and accompanying common warrant of $1.00, the last reported sale price of our
• $0 — d to the public in this offering, minus $0.001, and the exercise price of each pre
• $0.001 — rice of each pre-funded warrant will be $0.001 per share. The pre-funded warrants will
• $1.00 — rted sale price of our common stock was $1.00. The public offering price per share of
• $2.9 million — h and cash equivalents of approximately $2.9 million. The estimated preliminary cash and c
• $9.0 m — xpenses payable by us, of approximately $9.0 million, assuming a public offering price
• $4.35 — average exercise price of approximately $4.35 per share; 123,892 shares of common s

Filing Documents

• onvo-20240430.htm (S-1/A) — 3989KB
• onvo-ex1_1.htm (EX-1.1) — 170KB
• onvo-ex4_2.htm (EX-4.2) — 136KB
• onvo-ex4_3.htm (EX-4.3) — 154KB
• onvo-ex5_1.htm (EX-5.1) — 28KB
• onvo-ex10_42.htm (EX-10.42) — 280KB
• onvo-ex23_1.htm (EX-23.1) — 4KB
• onvo-exfiling_fees.htm (EX-FILING FEES) — 58KB
• img8932946_0.jpg (GRAPHIC) — 5KB
• img8932946_1.jpg (GRAPHIC) — 5KB
• img64644534_0.jpg (GRAPHIC) — 13KB
• img64644534_1.jpg (GRAPHIC) — 8KB
• img64644534_2.jpg (GRAPHIC) — 13KB
• img64644534_3.jpg (GRAPHIC) — 8KB
• 0000950170-24-050663.txt (&nbsp;) — 12860KB
• onvo-20240430.xsd (EX-101.SCH) — 1351KB
• onvo-20240430_htm.xml (XML) — 1953KB

Use of Proceeds

Use of Proceeds 32 Capitalization 33

Management's Discussion and Analysis of Financial Condition and Results of Operation

Management's Discussion and Analysis of Financial Condition and Results of Operation 41 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 50

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 51

Description of Capital Stock

Description of Capital Stock 52 Management 58 Director Compensation 61

Executive Compensation

Executive Compensation 62 Equity Compensation Plan Information 69 Certain Relationships and Related Party Transactions 71 Principal Stockholders 71 Material U.S. Federal Income Tax Considerations for Non-U.S. Holders 73 Plan of Distribution 78 Legal Matters 80 Experts 80 Where You Can Find More Information 80 Disclosure of Commission Position on Indemnification for Securities Act Liabilities 81 i About this Prospectus You should rely only on the information contained in this prospectus. We have not authorized anyone to provide you with information other than the information that we have provided or incorporated by reference in this prospectus and your reliance on any unauthorized information or representation is at your own risk. This prospectus may be used only in jurisdictions where offers and sales of these securities are permitted. You should assume that the information appearing in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus, or any sale of our securities. Our business, financial condition and results of operations may have changed since those dates. The information appearing in this prospectus and any free writing prospectus that we have authorized for use in connection with this offering is accurate only as of its respective date, regardless of the time of delivery of the respective document or of any sale of securities covered by this prospectus. You should not assume that the information contained in this prospectus, or in any free writing prospectus that we have authorized for use in connection with this offering, is accurate as of any date other than the respective dates thereof. We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including

Use of proceeds

Use of proceeds We expect to receive net proceeds, after deducting estimated placement agent fees and estimated expenses payable by us, of approximately $9.0 million, assuming a public offering price of $1.00 3 per share and common warrant, the last reported sale price of our common stock on the Nasdaq Capital Market on April 26, 2024, after deducting commissions and estimated offering expenses payable by us, and assuming no sale of any pre-funded warrants and no exercise of common warrants. We intend to use the net proceeds from this offering for working capital and general corporate purposes, which could include capital expenditures, research and development expenditures, regulatory affairs expenditures, clinical trial expenditures, legal expenditures, including intellectual property protection and maintenance expenditures, acquisitions of new technologies and investments, business combinations and the repurchase of capital stock. See " Use of Proceeds " on page 32 for more information.

Risk factors

Risk factors Investing in our securities involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment. You should carefully consider the information set forth in the " Risk Factors " section beginning on page 10. Nasdaq Capital Market trading symbol Our common stock is listed on the Nasdaq Capital Market under the symbol "ONVO." There is no established trading market for the common warrants or the pre-funded warrants, and we do not expect a trading market to develop. We do not intend to list the common warrants or pre-funded warrants on any securities exchange or other trading market. Without a trading market, the liquidity of the common warrants and pre-funded warrants will be extremely limited. The number of shares immediately outstanding following this offering is based on 9,838,755 shares of common stock outstanding as of December 31, 2023 and also gives effect to 1,590,321 shares of our common stock sold and issued through an "at the market offering" pursuant to a Sales Agreement that we entered into with H.C. Wainwright & Co., LLC and JonesTrading Institutional Services LLC on March 16, 2018 (the "Sales Agreement") and excludes: 695,459 shares of common stock issuable upon the exercise of stock options outstanding at a weighted average exercise price of approximately $4.35 per share; 123,892 shares of common stock issuable upon the vesting and settlement of outstanding restricted stock units; 1,000 shares of common stock avai

View Full Filing

View this S-1/A filing on SEC EDGAR